Recurrent and new primary cancer risk in adult patients with idiopathic inflammatory myositis and a history of malignancy
Authors' conclusion
In our tertiary referral centre, approximately one quarter of adult IIM patients who had a cancer diagnosis in the three years before IIM onset went on to develop an additional malignancy, either a recurrence or a new primary.
Study context
- Population
- Adult idiopathic inflammatory myopathies (IIM) patients with a documented cancer history, Johns Hopkins Myositis Center, enrolled 2003–2024280 with cancer history
- Participants
- 2,476 patients
- Exposure
- Cancer-free vs Cancer recurrence vs New primary cancer
- Cancer-freen = 29
- Cancer recurrencen = 6
- New primary cancern = 4
- Outcome
- Recurrent and new primary cancer development after IIM symptom onset
Methodological detailssingle-centre, tertiary referral centre
- Single-centre
- Tertiary referral centre
Main finding
As reported in the abstract
Cancer after IIM onset in patients with cancer diagnosed within 3 years before IIM onset (n=39) · median follow-up 5.5 (IQR 6.7) years
Observational data: associations, not effects.
Further findings
| Outcome | Cancer recurrence | New primary cancer |
|---|---|---|
| Time from index cancer to subsequent cancer | median 2.4 (IQR 1.6) years | 1.4 (IQR 1.0) years |
Cancer history among IIM patients
- Cancer history
- 280 (11%)
- Cancer diagnosed within 3 years before IIM symptom onset
- 39 (14%)
Original publication
Recurrent and new primary cancer risk in adult patients with idiopathic inflammatory myositis and a history of malignancy. Clin Exp Rheumatol. Published 24 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →